Analysis And Epidemiology Of Viral Hepatitis Illnesses In Khorazm Region

Abstract

According to the World Health Organization, liver cirrhosis is the tenth leading cause
of death among all diseases. Despite the development of a number of recommendations worldwide in
recent years, there is a sharp difference between the drugs used in the pharmacotherapy of liver
diseases and the drugs indicated in the treatment standards. This, in turn, requires deep pharmaco
epidemiological research [1]. The process of treating patients with chronic liver diseases requires
large financial costs. These are not only the costs of treatment, but also indirect costs, which are
associated with temporary loss of working capacity [2]. Epidemiological control of anthroponoses is
multifaceted, a dynamic study of the disease, not only operative control of the disease, but also a deep
investigation of the ecology, biology and distribution area of the causative agent. Viral hepatitis is
one of the most common viral infectious diseases in the world. According to the information provided
by the World Health Organization, 2 billion people are infected with viral hepatitis on earth, which
corresponds to 1 out of every 3 people on earth [3]. Every year, parenteral viral hepatitis kills more
than 1 million people worldwide, which is equal to the number of deaths from tuberculosis and more
than the number of deaths from HIV. In 2021, despite the widespread use of a highly effective vaccine
against viral hepatitis V, 1.5 million people were infected with hepatitis V [4]. The medical and social
conditions of Uzbekistan include the hyperendemic region due to the specificity of the number of
family members, different levels of virus infection in the region due to the age structure, and the
spread of infection due to the ethnic identity of the local population [5,6]. In screening studies
conducted by a number of authors, it was found that 5.6% of healthy population tested in our country
have anti-HCV and 8.3% have HBsAg.